Breakthrough GLP-1 implant promises major weight-loss benefits for petsBreakthrough GLP-1 implant promises major weight-loss benefits for pets
The world’s first GLP-1 weight loss treatment is being administered for pets on an experimental basis. The first cat was successfully dosed in the MEOW-1 study of OKV-119 – an investigational “ultra-long acting” GLP-1 implant, which, according to a press release, is being developed for weight management in cats. OKAVA Pharmaceuticals, the San Francisco-based manufacturer Read More
After NIH grant cuts, breast cancer research at Harvard slowed, and lab workers leftAfter NIH grant cuts, breast cancer research at Harvard slowed, and lab workers left
Amid NIH funding delays, reversals and uncertainty, a scientist at Harvard who studies breast cancer has lost one-third of her lab employees and wonders if she can continue her research experiments.
FDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 DiabetesFDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 Diabetes
The US Food and Drug Administration (FDA) recently approved Novo Nordisk’s oral semaglutide, marketed as Rybelsus, to reduce the risk of major adverse cardiac events in adults with type 2 diabetes who are at high risk of these conditions. The US Food and Drug Administration (FDA) recently approved Novo Nordisk’s oral semaglutide, marketed as Rybelsus, Read More
GLP-1 receptor agonists show little effect on obesity-related cancer riskGLP-1 receptor agonists show little effect on obesity-related cancer risk
1. In this systematic review and meta-analysis, use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) was not associated with a significant change in the risk of thyroid, pancreatic, breast, or kidney cancer. 2. Findings were consistent across subgroups, including by follow-up duration and among trials enrolling patients with type 2 diabetes, overweight or obesity, or both Read More
GLP-1 drugs have ‘little or no effect’ on risk of obesity-related cancers, study suggestsGLP-1 drugs have ‘little or no effect’ on risk of obesity-related cancers, study suggests
Popular weight-loss drugs “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related cancers, new research suggests. Popular weight-loss drugs “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related cancers, new research suggests.
GLP-1 receptor agonists likely have little or no effect on obesity-related cancer risk, research showsGLP-1 receptor agonists likely have little or no effect on obesity-related cancer risk, research shows
A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or overweight or obesity. A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or Read More
Her food cravings vanished on Mounjaro then roared backHer food cravings vanished on Mounjaro then roared back
Deep-brain recordings showed that Mounjaro and Zepbound briefly shut down the craving circuits linked to food noise in a patient with severe obesity. Her obsessive thoughts about food disappeared as the medication quieted the nucleus accumbens, the brain’s reward hub. Deep-brain recordings showed that Mounjaro and Zepbound briefly shut down the craving circuits linked to Read More
Ozempic can reduce metabolic risks in schizophrenia patients, multicenter study findsOzempic can reduce metabolic risks in schizophrenia patients, multicenter study finds
Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with schizophrenia spectrum disorders, according to a study published in JAMA Psychiatry. Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with schizophrenia spectrum disorders, according to a Read More
STAT+: Driven by GLP-1s, prescription drug spending explodes at major health insurersSTAT+: Driven by GLP-1s, prescription drug spending explodes at major health insurers
Health insurance companies have lamented fast-rising medical expenses for more than two years. This year is no different as Americans continue to get more care than insurers expected. One of the main culprits of that higher spending: prescription drugs, and GLP-1s in particular. Some insurers spent more on drugs in the first nine months of Read More
Tai Chi for Insomnia; WHO Guidance on GLP-1 DrugsTai Chi for Insomnia; WHO Guidance on GLP-1 Drugs
(MedPage Today) — TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of Texas Tech Health El Paso, look at the top medical… (MedPage Today) — TTHealthWatch is a weekly podcast from Texas Tech. In it, Read More